So there is a possibility of course that safety at any time might emerge as you start to look at more and more patients. By having the 3 milligram dose, it also derisks any potential safety — emerging safety signal that might exist. And this has occurred — I’ve had this occur in another program at previous company other than where we — the backup dose, it was good that we actually had it in there because there were some tolerability issues and it allowed the lower dose to get approved. So this was something actually at the behest of the agency. I actually thought it was a good idea. It’s the reason why our numbers have bumped up. Previously, I was telling investors with one dose and one placebo the trial could probably be adequately powered at somewhere around 220, 230 patients when you add this additional arm and you still want to be over 90% this is how we get closer to 264.
So I think it’s a combination of de-risking for a potential effect that may or may not emerge. We don’t think it will. And it gives us another shot on goal.
Sean Kim: Okay. Thank you. And how about the timing and the sequence of different events. So from clinicaltrials.gov information, it looks like the trial is scheduled or expected to complete in May €˜24, early €˜25. So is that the kind of ballpark timing that I should be kind of expecting the study to complete? And also related to that is, for the other programs in . Would you be expecting that to complete the EFZO-FIT trial and see the outcome before kind of embarking on Phase 2 for the other programs or the three programs be a sequence somewhere in between as far as timeline goes? Thank you.
Sanjay Shukla: But at this point, I’ll answer the second part first. At this point, we’re focused on this one indication. So while we have some encouraging signals with additional ILD indications, right now, we’re focused on this trial and focused on getting it done. When you look at clinicaltrials.gov, we have to put down something. This is our best early estimate. But as we get into enrollment, I’ll be able to look at that and say, does that timing still make sense? Should it be pulled in? Should it go out further? This will be predicated on how we do here really over the next six months. But most sponsors have to put something an early estimate. And I think we have that for something like January 2025 right now.
Sean Kim: Okay. Thank you. And I guess my last question is about the cash runway. I haven’t seen the guided number on the press release, but I just want to make sure if I’m not missing anything. Have you guided the cash runway and also now that you are not pursuing 2810 development, how much of additional kind of expansion that we cannot expect from, in terms of cash runway from kind of not working on 2810?
Jill Broadfoot: Yes. This is Jill. We don’t typically give a cash runway because we look at it by projects. And like we said during the script, we do have financial and strategic plans to be able to get through the data readout for EFZO-FIT. So that’s using our current cash will be getting milestones from Kyorin and then also use of the current equity vehicles that we have out there right now. We’re saving some money from not doing 2810 in the clinic like we just discussed with, Yale. Those types of trials just generally typically or maybe around $10 million-ish, but it’s more — that’s just the cost of the trial. It’s more the time that those take and the overhead that is needed just to continue running those over a period of two or less longer years.
